首页> 外文期刊>JAMA: the Journal of the American Medical Association >Association between azithromycin therapy and duration of bacterial shedding among patients with shiga toxin-producing enteroaggregative Escherichia coli O104:H4
【24h】

Association between azithromycin therapy and duration of bacterial shedding among patients with shiga toxin-producing enteroaggregative Escherichia coli O104:H4

机译:阿奇霉素治疗与产志贺毒素的肠聚集性大肠杆菌O104:H4患者细菌脱落持续时间之间的关联

获取原文
获取原文并翻译 | 示例
       

摘要

Context: An outbreak of Shiga toxin-producing enteroaggregative Escherichia coli (STEC O104:H4) infection with a high incidence of hemolytic uremic syndrome (HUS) occurred in Germany in May 2011. Antibiotic treatment of STEC infection is discouraged because it might increase the risk of HUS development. However, antibiotic therapy is widely used to treat enteroaggregative E coli infection. In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab. Objective: To analyze the duration of bacterial shedding in patients with STEC infection who did and did not receive oral azithromycin therapy. Design, Setting, and Patients: At a single center in Lübeck, Germany, 65 patients with STEC infection, including patients with HUS as well as STEC-infected outpatients without manifestation of HUS, were investigated between May 15 and July 26, 2011, and were monitored for a mean of 39.3 days after onset of clinical symptoms. Main Outcome Measure; Carriage of STEC after azithromycin therapy. Results: Twenty-two patients received oral azithromycin and 43 patients did not receive antibiotic treatment. Among antibiotic-treated patients, long-term STEC carriage (>28 days) was observed in 1 of 22 patients (4.5%; 95% CI, 0%-13.3%) compared with 35 of 43 patients (81.4%; 95% CI, 69.8%-93.0%) who were not treated with antibiotics (P<.001). All 22 patients receiving azithromycin treatment had at least 3 STECnegative stool specimens after the completion of treatment, and no recurrence of STEC was observed in these patients. As proof of principle, 15 patients who initially were not treated with antibiotics and were long-term STEC carriers were treated with oral azithromycin given for 3 days and subsequently had negative stool specimens. Conclusion: Treatment with azithromycin was associated with a lower frequency of long-term STEC O104:H4 carriage.
机译:背景:2011年5月在德国爆发了发生志贺毒素的产肠聚合性大肠杆菌(STEC O104:H4)感染,并伴有溶血性尿毒症综合征(HUS)的高发。不鼓励对STEC感染进行抗生素治疗,因为这可能会增加风险HUS开发。然而,抗生素疗法被广泛用于治疗肠聚合性大肠杆菌感染。在德国爆发中,作为C5抗体依库丽单抗治疗方案的一部分,大量患者接受了阿奇霉素的预防性治疗。目的:分析接受和不接受阿奇霉素治疗的STEC感染患者细菌脱落的持续时间。设计,设置和患者:2011年5月15日至2011年7月26日,在德国吕贝克的一个中心对65例STEC感染患者进行了调查,包括HUS患者以及没有HUS表现的STEC感染门诊。在临床症状发作后平均监测39.3天。主要结果指标;阿奇霉素治疗后STEC的运输。结果:22例接受口服阿奇霉素治疗,43例未接受抗生素治疗。在接受抗生素治疗的患者中,有22位患者中有1位(4.5%; 95%CI,0%-13.3%)观察到长期STEC转运(> 28天),而43位患者中有35位(81.4%; 95%CI) (69.8%-93.0%)的人未接受抗生素治疗(P <.001)。治疗结束后,接受阿奇霉素治疗的所有22例患者至少有3例STEC阴性大便标本,这些患者均未观察到STEC复发。作为原理证明,对15例最初未接受抗生素治疗且长期为STEC携带者的患者给予口服阿奇霉素治疗3天,随后粪便样本阴性。结论:阿奇霉素治疗与长期STEC O104:H4转运的频率较低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号